Research & Clinical Trials

The research mission of the Division of Gastroenterology is to advance the understanding, diagnosis, treatment & prevention of diseases of the digestive tract. Narrow your search for a program by using the search box and/or filters.
23 results
  • research core

Clinical Core

The CSIBD Clinical Core provides an infrastructure to facilitate the translation of basic research findings into a clinical setting.

  • research lab

Corcoran Lab

The Corcoran laboratory focuses on developing new and effective therapies for gastrointestinal cancers, such as colorectal and pancreatic cancers, by targeting the specific survival signals that are active in a given patient's cancer.

  • research lab

GI Cancers – Daniel C. Chung Laboratory

Our laboratory seeks to gain new insights into the molecular pathogenesis of tumors of the GI tract. Our particular areas of interest are colon cancer, neuroendocrine tumors, angiogenesis, hypoxia, hereditary cancers, and genetic instability. We seek to identify molecular targets that can ultimately guide therapeutic strategies.

  • research core

Genetic Animal Models Core

Our core develops genetic technologies and model systems aimed at investigating genes and pathways to yield insight into how human genomic variants affect the pathogenesis of IBD.

  • research lab

Giallourakis Laboratory: Cosmas Giallourakis, MD

The lab is interested in two major topics: 1) The role of post-transcriptional RNA chemical modifications (“epitranscriptomics”) on biological functions 2) The role of RNA-binding protein (RBP) interactomes in epigenetic and post-transcriptional regulatory systems implicated in human autoimmune diseases

  • research lab

Clinical trials of antiviral therapy for chronic viral hepatitis - Dienstag

Dr. Dienstag is an experienced clinical investigator in the area of viral hepatitis (trials of antiviral therapies for chronic hepatitis B and C). Between 2000 and 2010, he was the site-PI of a national trial of maintenance antiviral therapy for patients refractory to treatment for chronic hepatitis C, the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial.

Showing 1 - 10 of 23 results